Compare BRC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | BLTE |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 1984 | 2022 |
| Metric | BRC | BLTE |
|---|---|---|
| Price | $77.32 | $148.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $149.00 |
| AVG Volume (30 Days) | 224.3K | ★ 244.0K |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 0.61 | N/A |
| EPS | ★ 4.08 | N/A |
| Revenue | ★ $1,541,827,000.00 | N/A |
| Revenue This Year | $6.76 | N/A |
| Revenue Next Year | $3.84 | N/A |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 11.21 | N/A |
| 52 Week Low | $62.70 | $49.00 |
| 52 Week High | $84.03 | $160.55 |
| Indicator | BRC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 68.29 |
| Support Level | $77.33 | $140.07 |
| Resistance Level | $79.36 | $154.00 |
| Average True Range (ATR) | 1.90 | 12.43 |
| MACD | -0.13 | 0.74 |
| Stochastic Oscillator | 41.54 | 78.20 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.